Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 480

1.

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM.

Cancer Res. 2000 Sep 15;60(18):5165-70.

2.

Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.

Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA.

Clin Cancer Res. 2001 Apr;7(4):962-70.

3.

Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.

Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS.

Clin Cancer Res. 2006 Sep 1;12(17):5199-206.

4.

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.

Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP.

Clin Cancer Res. 2007 Feb 1;13(3):1045-52.

5.

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.

Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM.

Mol Cancer Ther. 2007 Jan;6(1):51-60. Epub 2007 Jan 11.

6.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1. Epub 2010 Sep 14.

PMID:
20838997
7.

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.

Mol Cancer Ther. 2009 Jun;8(6):1596-605. doi: 10.1158/1535-7163.MCT-08-1004. Epub 2009 Jun 9.

8.

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW.

J Natl Cancer Inst. 1996 Jun 19;88(12):794-801.

PMID:
8637045
9.
11.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM.

Cancer Res. 2001 Dec 1;61(23):8492-7.

12.
13.

Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, Richon VM.

Anticancer Res. 2002 May-Jun;22(3):1497-504.

PMID:
12168829
14.

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.

Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN.

J Cell Biochem. 2004 May 15;92(2):223-37.

PMID:
15108350
15.

Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.

Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP.

Clin Cancer Res. 2003 Nov 15;9(15):5749-55.

16.

Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.

Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP.

Clin Cancer Res. 2006 Sep 15;12(18):5570-7.

17.

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.

Ugur HC, Ramakrishna N, Bello L, Menon LG, Kim SK, Black PM, Carroll RS.

J Neurooncol. 2007 Jul;83(3):267-75. Epub 2007 Feb 20.

PMID:
17310267
18.
19.

Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.

Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K.

Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):546-52. doi: 10.1016/j.ijrobp.2009.01.068.

PMID:
19427556
20.

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.

Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R.

Prostate. 2007 Aug 1;67(11):1182-93.

PMID:
17520666

Supplemental Content

Support Center